Co-Authors
This is a "connection" page, showing publications co-authored by Junko Matsuzaki and Richard Koya.
Connection Strength
0.686
-
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022 03 16; 14(636):eabg8402.
Score: 0.203
-
A rare population of tumor antigen-specific CD4+CD8+ double-positive aß T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells. J Immunother Cancer. 2019 01 09; 7(1):7.
Score: 0.162
-
Correction to: Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2899.
Score: 0.053
-
Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2881-2898.
Score: 0.051
-
CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. J Immunother Cancer. 2021 10; 9(10).
Score: 0.049
-
WHSC1/NSD2 regulates immune infiltration in prostate cancer. J Immunother Cancer. 2021 02; 9(2).
Score: 0.047
-
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J Immunother Cancer. 2019 06 20; 7(1):156.
Score: 0.042
-
Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight. 2019 03 07; 4(5).
Score: 0.041
-
Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy. Cancer Immunol Res. 2018 05; 6(5):594-604.
Score: 0.038